GAIN THERAPEUTICS INC (GANX)

NASDAQHealth CareBiotechnologySnapshot 2026-10-23

$1.26-2.33%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge GAIN THERAPEUTICS INC’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	33,333
EPS	—	-0.13
Annual ending 2026-12-31
Revenue	—	50,000
EPS	—	-0.497
Annual ending 2027-12-31
Revenue	—	225,000
EPS	—	-0.651

Management figures unavailable.

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Limit net losses during clinical investment	The company aims to advance clinical programs despite ongoing losses.	Broken	Net loss worsens beyond -$5.6M per quarter	Net income: $-4.676M FY2026-Q2; GAAP. Published target: Net loss no worse than -$5.6M per quarter. Target period is not explicitly aligned with this observation. Source published Aug 11, 2026-4,675,571 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 65564bb7-0b2e-4789-8200-03bbf66b84cd. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 2 of last 2 quarters. R&D expenses decreased from $2.8M in 2025-Q2 to $2.1M in 2026-Q2, showing some cost control. Cash declined from $20.8M at 2025-Q4 to $13.1M at 2026-Q2, consistent with ongoing clinical spend. Management maintains financial discipline amid development, trajectory shows partial cost reduction but cash burn continues. Delivery assessment Oct 24, 2026
Manage operating expenses amid clinical development	Management is focused on financial discipline amid development.	Broken	Operating loss worsens beyond -$5.4M per quarter	Operating income: $-4.682M FY2026-Q2; GAAP. Published target: Operating loss no worse than -$5.4M in 2026-Q1 equivalent quarters going forward. Target period is not explicitly aligned with this observation. Source published Aug 11, 2026-4,681,652 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 65564bb7-0b2e-4789-8200-03bbf66b84cd. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 2 of last 2 quarters. R&D expenses decreased from $2.8M in 2025-Q2 to $2.1M in 2026-Q2, showing some cost control. Cash declined from $20.8M at 2025-Q4 to $13.1M at 2026-Q2, consistent with ongoing clinical spend. Management maintains financial discipline amid development, trajectory shows partial cost reduction but cash burn continues. Delivery assessment Oct 24, 2026
Advance Phase 2 study following FDA IND clearance	Gain Therapeutics has FDA clearance to start Phase 2 trials in Q3 2026.	Intact	Phase 2 study initiation delayed beyond Q3 2026	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 2 of last 2 quarters. Management confirmed FDA IND clearance for rexaceract in 2026-Q2 and plans to initiate Phase 2 clinical trial in Q3 2026. This trajectory matches management's stated timeline and shows delivery on regulatory milestone enabling clinical advancement. Delivery assessment Oct 24, 2026

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS: comparable history unavailable.

FY2027 revenue$0.00B

$0.00B → $0.00B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	Unavailable	$225,000	3 / 5
2026-07-25	Unavailable	$225,000	3 / 5
2026-07-26	Unavailable	$225,000	3 / 5
2026-07-27	Unavailable	$225,000	3 / 5
2026-07-28	Unavailable	$0	3 / 5
2026-07-29	Unavailable	$225,000	3 / 5
2026-07-30	Unavailable	$0	3 / 5
2026-07-31	Unavailable	$0	3 / 5
2026-08-01	Unavailable	$225,000	3 / 5
2026-08-02	Unavailable	$225,000	3 / 5
2026-08-03	Unavailable	$0	3 / 5
2026-08-04	Unavailable	$0	3 / 5
2026-08-05	Unavailable	$225,000	3 / 5
2026-08-06	Unavailable	$225,000	3 / 5
2026-08-07	Unavailable	$225,000	3 / 5
2026-08-08	Unavailable	$0	3 / 5
2026-08-09	Unavailable	$0	3 / 5
2026-08-10	Unavailable	$0	3 / 5
2026-08-12	Unavailable	$0	3 / 5
2026-08-13	Unavailable	$0	3 / 5
2026-08-14	Unavailable	$225,000	3 / 5
2026-08-15	Unavailable	$225,000	3 / 5
2026-08-16	Unavailable	$225,000	3 / 5
2026-08-17	Unavailable	$225,000	3 / 5
2026-08-18	Unavailable	$225,000	3 / 5
2026-08-19	Unavailable	$225,000	3 / 5
2026-08-20	Unavailable	$225,000	3 / 5
2026-08-21	Unavailable	$225,000	3 / 5
2026-08-22	Unavailable	$225,000	3 / 5
2026-08-23	Unavailable	$225,000	3 / 5
2026-08-24	Unavailable	$225,000	3 / 5
2026-08-25	Unavailable	$225,000	3 / 5
2026-08-26	Unavailable	$225,000	3 / 5
2026-08-27	Unavailable	$225,000	3 / 5
2026-08-28	Unavailable	$225,000	3 / 5
2026-08-29	Unavailable	$225,000	3 / 5
2026-08-30	Unavailable	$225,000	3 / 5
2026-08-31	Unavailable	$225,000	3 / 5
2026-09-01	Unavailable	$225,000	3 / 5
2026-09-02	Unavailable	Unavailable	3 / 4
2026-09-03	Unavailable	$225,000	3 / 5
2026-09-04	Unavailable	$225,000	3 / 5
2026-09-05	Unavailable	$225,000	3 / 5
2026-09-06	Unavailable	$225,000	3 / 5
2026-09-07	Unavailable	$225,000	3 / 5
2026-09-08	Unavailable	$225,000	3 / 5
2026-09-09	Unavailable	$225,000	3 / 5
2026-09-10	Unavailable	$225,000	3 / 5
2026-09-11	Unavailable	$225,000	3 / 5
2026-09-12	Unavailable	$225,000	3 / 5
2026-09-13	Unavailable	$225,000	3 / 5
2026-09-14	Unavailable	$225,000	3 / 5
2026-09-15	Unavailable	$225,000	3 / 5
2026-09-16	Unavailable	$225,000	3 / 5
2026-09-17	Unavailable	$225,000	3 / 5
2026-09-18	Unavailable	$225,000	3 / 5
2026-09-19	Unavailable	$225,000	3 / 5
2026-09-20	Unavailable	$225,000	3 / 5
2026-09-21	Unavailable	$225,000	3 / 5
2026-09-22	Unavailable	$225,000	3 / 5
2026-09-23	Unavailable	$225,000	3 / 5
2026-09-24	Unavailable	$225,000	3 / 5
2026-09-25	Unavailable	$225,000	3 / 5
2026-09-26	Unavailable	$225,000	3 / 5
2026-09-27	Unavailable	$225,000	3 / 5
2026-09-28	Unavailable	$225,000	3 / 5
2026-09-29	Unavailable	$225,000	3 / 5
2026-09-30	Unavailable	$225,000	3 / 5
2026-10-01	Unavailable	$225,000	3 / 5
2026-10-02	Unavailable	$225,000	3 / 5
2026-10-03	Unavailable	$225,000	3 / 5
2026-10-04	Unavailable	$225,000	3 / 5
2026-10-05	Unavailable	$225,000	3 / 5
2026-10-06	Unavailable	$225,000	3 / 5
2026-10-07	Unavailable	$225,000	4 / 5
2026-10-08	Unavailable	$225,000	4 / 5
2026-10-09	Unavailable	$225,000	4 / 5
2026-10-10	Unavailable	$225,000	4 / 5
2026-10-11	Unavailable	$225,000	4 / 5
2026-10-12	Unavailable	$225,000	4 / 5
2026-10-13	Unavailable	$225,000	4 / 5
2026-10-14	Unavailable	$225,000	4 / 5
2026-10-15	Unavailable	$225,000	4 / 5
2026-10-16	Unavailable	$225,000	4 / 5
2026-10-17	Unavailable	$225,000	4 / 5
2026-10-18	Unavailable	$225,000	4 / 5
2026-10-19	Unavailable	$225,000	4 / 5
2026-10-20	Unavailable	$225,000	4 / 5
2026-10-21	Unavailable	$225,000	4 / 5
2026-10-22	Unavailable	$225,000	4 / 5
2026-10-23	Unavailable	$225,000	4 / 5
2026-10-24	Unavailable	$225,000	4 / 5

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold	Sell*
2026-05-01	5	0	0
2026-06-01	5	0	0
2026-07-01	5	0	0
2026-08-01	5	0	0
2026-09-01	5	0	0
2026-10-01	5	0	0

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 5 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades1 maintains

Recent actions · Sep 25–Oct 24 · 1 recorded

Price-target changes

30 days

○ Previous · ● Latest · common dollar scale

BTIGOct 5

$5.00New observation · no comparable prior

$0$2.75$5.50

0 raises · 0 cuts · 0 unchanged · 1 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Limit net losses during clinical investmentPublished status: Broken
Manage operating expenses amid clinical developmentPublished status: Broken
Advance Phase 2 study following FDA IND clearanceDirect metric needs a verified mapping

Next proof point

Nov 11, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

2.2%Typical daily move · historical

Downside history

-71.5%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

GAIN THERAPEUTICS INC outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is speculative clinical-stage growth, not an established earnings compounder. The long-term thesis is in a watch state: management has advanced some research milestones, but losses, high risk, and recent performance below its industry cohort keep the evidence mixed.

What's priced into GAIN THERAPEUTICS INC

The valuation is tagged as stretched, with a modeled premium of about 32% versus peers and low confidence in that estimate. The evidence points to expectations tied partly to pipeline optionality, meaning the value of possible future programs, but does not specify which outcomes the market assumes.

What the fundamentals likely do

Near term, results are likely to remain difficult to assess because GANX is loss-making and its recent financial performance is neutral and below its industry cohort. Management has confirmed FDA clearance for rexaceract and plans a Phase 2 trial, while final Phase 1b data and an indication choice for GT-04686 are expected later in 2026; delivery remains mixed. The next report carries meaningful execution risk, and the recent CEO transition and litigation add uncertainty.

What GAIN THERAPEUTICS INC hinges on

The multi-year thesis depends on advancing rexaceract into Phase 2, reporting the planned 90-day Phase 1b analysis, and moving GT-04686 toward IND-enabling studies. A guidance cut or weaker employment data could weigh on the near-term outlook, while continued strength among major Healthcare companies could support sector momentum. The available evidence does not establish the clinical outcomes needed to validate the pipeline.